158 related articles for article (PubMed ID: 5756166)
21. [Glybenclamide and its place among sulfanylureas in the treatment of diabetes mellitus].
Cabezas Cerrato J; Fernández-Cruz A; Fernández-Cruz A
Rev Clin Esp; 1970 May; 117(4):375-86. PubMed ID: 5471527
[No Abstract] [Full Text] [Related]
22. A clinical trial of glybenclamide (HB-419): a new oral hypoglycemic agent.
Choudhry AS; Gomez E; McKendry JB
Appl Ther; 1970 May; 12(5):28-9. PubMed ID: 4912481
[No Abstract] [Full Text] [Related]
23. Tolazamide in the treatment of diabetes mellitus.
Baird IM; Evans JH; Hirst J; Longson D
Practitioner; 1967 Feb; 198(184):264-7. PubMed ID: 6038982
[No Abstract] [Full Text] [Related]
24. [Treatment of diabetes mellitus with the E.R. 105 oral preparation].
Domingo Gutiérrez AJ
Rev Iber Endocrinol; 1969; 16(96):449-63. PubMed ID: 4906090
[No Abstract] [Full Text] [Related]
25. [Treatment with a new antidiabetic: glybenclamide].
Madsen SN; Persson I
Ugeskr Laeger; 1970 Jan; 132(4):143-7. PubMed ID: 5442953
[No Abstract] [Full Text] [Related]
26. [Effect and tolerance of HB 419 in out-patient treated diabetics].
Bauer G; Kloppe W; Schubert PU
Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1434-6. PubMed ID: 5394467
[No Abstract] [Full Text] [Related]
27. Tolinase--a new oral antidiabetic drug.
Med Lett Drugs Ther; 1966 Sep; 8(19):77-8. PubMed ID: 5971398
[No Abstract] [Full Text] [Related]
28. [Preliminary results with a new oral antidiabetic drug of the sulfanylurea series: glibenclamide or HB 419].
Marocco F; Patrito G
Minerva Med; 1970 Dec; 61(97):5525-42. PubMed ID: 5494124
[No Abstract] [Full Text] [Related]
29. Glucose and insulin after diet and tolazamide treatment.
Sheldon J
Br Med J; 1970 Oct; 4(5729):246. PubMed ID: 5472796
[No Abstract] [Full Text] [Related]
30. [Clinical experiences with tolazamide].
Laffi GC; Bruno GM
Minerva Med; 1965 Sep; 56(75):3213-5. PubMed ID: 5320010
[No Abstract] [Full Text] [Related]
31. [Suppression of thyroid gland function by prolonged use of HB 419].
Stötter G; Szabo J; Köhler W
Arzneimittelforschung; 1969 Aug; 19(8):Suppl:1436-9. PubMed ID: 4186530
[No Abstract] [Full Text] [Related]
32. Glucose and insulin secretory response patterns following diet and tolazamide therapy in diabetes.
Turtle JR
Br Med J; 1970 Sep; 3(5723):606-10. PubMed ID: 5470087
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience with the oral antidiabetic compound, tolazamide.
McKendry JB; Gfeller KF
Can Med Assoc J; 1967 Mar; 96(9):531-5. PubMed ID: 6019353
[TBL] [Abstract][Full Text] [Related]
34. [Study of oral hypoglycemic agents. VI. Comparative study on acute oral overload using tolbutamide and tolazamide in normal and diabetic subjects. Various aspects of the prolonged use of tolazamide in comparison with other sulfonylureas].
Pereira VG; Wajchenberg BL; Shnaider J
Arq Bras Endocrinol Metabol; 1965 Aug; 14(2):133-42. PubMed ID: 5322747
[No Abstract] [Full Text] [Related]
35. [Transaminase activity of the blood and bile in diabetes mellitus].
Vladkovskiĭ IK; Mokhun' IK; Liashuk PM; Splavskiĭ OI; Ivanenko EI
Vrach Delo; 1981 Jun; (6):74-5. PubMed ID: 7257304
[No Abstract] [Full Text] [Related]
36. [Several functional changes in the livers of patients with diabetes mellitus].
Minchev M; Raiĭkova M; Stanchev I; Kartaleva M; Nochev I
Vutr Boles; 1976; 15(4):50-6. PubMed ID: 188261
[TBL] [Abstract][Full Text] [Related]
37. Raised gamma glutamyl transferase in Nigerian diabetics: possible clinical implications.
Oli JM; Onwuamaeze IC; Okonkwo PO
J Trop Med Hyg; 1983 Oct; 86(5):179-83. PubMed ID: 6142119
[TBL] [Abstract][Full Text] [Related]
38. Clinical experience with glybenclamide in 100 non-ketotic diabetics.
Sahgal VK; Ahuja MM
Indian J Med Res; 1971 Feb; 59(2):251-8. PubMed ID: 4931412
[No Abstract] [Full Text] [Related]
39. [Multicentric clinical proof of a new oral antidiabetic glisoxepide (BS 4231). 3. Results of tolerance tests].
Kiesselbach NH; Blumenbach L; Lehnert J
Arzneimittelforschung; 1974 Mar; 24(0):447-52. PubMed ID: 4603694
[No Abstract] [Full Text] [Related]
40. [Experiences in the treatment of diabetics with the new oral hypoglycemic agent from the sulfonyl urea group].
Durić DS; Popović S
Med Glas; 1969; 23(5):92-7. PubMed ID: 4921012
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
